Cartia

Product NDC
50090-3051
11-digit product format
500903051
Labeler code
50090
Product ID
50090-3051_72ab8df9-1dc1-4677-8437-29f2448f8b8f
Type
HUMAN PRESCRIPTION DRUG
Nonproprietary name
Diltiazem Hydrochloride
Dosage form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Labeler
A-S Medication Solutions
Application
ANDA074752
Marketing category
ANDA
Marketing start
1998-07-09
Marketing end
0000-00-00
Substance
DILTIAZEM HYDROCHLORIDE
Active strength
120 mg/1
Pharmacologic classes
Calcium Channel Antagonists [MoA],Calcium Channel Blocker [EPC]
NDC exclude flag
No
Listing certified through
2020-12-31
Current FDA listing
Historical FDA.report record

NDC auxiliary status#

Explicit status records from FDA unfinished, excluded, and compounder auxiliary files. Absence of a row is not itself a regulatory status.

Dataset, Scope, Product NDC table
DatasetScopeProduct NDCPackage NDCCodeStatusReporting periodSource date
excluded productproduct50090-3051DDiscontinued by firm2026-07-31
excluded packagepackage50090-305150090-3051-0DDiscontinued by firm2026-07-31
excluded packagepackage50090-305150090-3051-1DDiscontinued by firm2026-07-31

Orange Book products#

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A074752-001CARTIA XTDILTIAZEM HYDROCHLORIDE180MGCAPSULE, EXTENDED RELEASE / ORALAB31998-07-09
A074752-002CARTIA XTDILTIAZEM HYDROCHLORIDE120MGCAPSULE, EXTENDED RELEASE / ORALAB31998-07-09
A074752-003CARTIA XTDILTIAZEM HYDROCHLORIDE240MGCAPSULE, EXTENDED RELEASE / ORALAB31998-07-09
A074752-004CARTIA XTDILTIAZEM HYDROCHLORIDE300MGCAPSULE, EXTENDED RELEASE / ORALAB31998-07-09

Therapeutic equivalence codes#

Application-product, TE code table
Application-productTE code
A074752-001AB3
A074752-002AB3
A074752-003AB3
A074752-004AB3

openFDA label cross-check#

Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Cartia XTDILTIAZEM HYDROCHLORIDEActavis Pharma, Inc.2dc2b889-8443-4f7f-83be-86c68e1798042026-04-30Warnings, Adverse reactionsExact identifier
Cartia XTDILTIAZEM HYDROCHLORIDEBryant Ranch Prepackde671934-25a8-4df6-b7a1-97e0337e9e2b2025-06-02Warnings, Adverse reactionsExact identifier
Cartia XTDILTIAZEM HYDROCHLORIDEBryant Ranch Prepacke02f5fad-6482-4d5d-91c5-0ae6b0ce15b82025-03-06Warnings, Adverse reactionsExact identifier
CARTIA XTDILTIAZEM HYDROCHLORIDEDirectRxdbfda3a5-5602-6e47-e053-2995a90ac07b2025-01-22Warnings, Adverse reactionsExact identifier

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

warnings

WARNINGS Cardiac Conduction: Diltiazem hydrochloride prolongs AV node refractory periods without significantly prolonging sinus node recovery time, except in patients with sick sinus syndrome. This effect may rarely result in abnormally slow heart rates (particularly in patients with sick sinus syndrome) or second- or third-degree AV block (13 of 3290 patients or 0.40%). Concomitant use of diltiazem with beta-blockers or digitalis may result in additive effects on cardiac conduction. A patient with Prinzmetal’s angina developed periods of asystole (2 to 5 seconds) after a single dose of 60 mg of diltiazem (see ADVERSE REACTIONS ). Congestive Heart Failure: Although diltiazem has a negative inotropic effect in isolated animal tissue preparations, hemodynamic studies in humans with normal ventricular function have not shown a reduction in cardiac index nor consistent negative effects on contractility (dP/dt). An acute study of oral diltiazem in patients with impaired ventricular function (ejection fraction 24% ± 6%) showed improvement in indices of ventricular function without significant decrease in contractile function (dP/dt). Worsening of congestive heart failure has been reported in patients with preexisting impairment of ventricular function. Experience with the use of diltiazem hydrochloride in combination with beta-blockers in patients with impaired ventricular function is limited. Caution should be exercised when using this combination. Hypotension: Decreases in blood pressure associated with diltiazem hydrochloride therapy may occasionally result in symptomatic hypotension. Acute Hepatic Injury: Mild elevations of transaminases with and without concomitant elevation in alkaline phosphatase and bilirubin have been observed in clinical studies. Such elevations were usually transient and frequently resolved even with continued diltiazem treatment. In rare instances, significant elevations in enzymes such as alkaline phosphatase, LDH, SGOT, SGPT, and other phenomena consistent with acute hepatic injury have been noted. These reactions tended to occur early after therapy initiation (1 to 8 weeks) and have been reversible upon discontinuation of drug therapy. The relationship to diltiazem hydrochloride is uncertain in some cases, but probable in some (see PRECAUTIONS ).

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

adverse reactions

ADVERSE REACTIONS Serious adverse reactions have been rare in studies carried out to date, but it should be recognized that patients with impaired ventricular function and cardiac conduction abnormalities have usually been excluded from these studies. The following table presents the most common adverse reactions reported in placebo-controlled angina and hypertension trials in patients receiving diltiazem hydrochloride extended-release capsule (once-a-day dosage) up to 360 mg with rates in placebo patients shown for comparison. Diltiazem Hydrochloride Extended-release Capsule (once-a-day dosage) Placebo-Controlled Angina and Hypertension Trials Combined Adverse Reactions Diltiazem Hydrochloride Extended-release Capsule (once-a-day dosage) (n=607) Placebo (n=301) Headache 5.4% 5.0% Dizziness 3.0% 3.0% Bradycardia 3.3% 1.3% AV Block First Degree 3.3% 0.0% Edema 2.6% 1.3% Asthenia 1.8% 1.7% In addition, the following events were reported infrequently (less than 1%) in angina or hypertension trials: Cardiovascular: Congestive heart failure, palpitations, syncope, ventricular extrasystoles. Nervous System: Abnormal dreams, amnesia, depression, gait abnormality, hallucinations, insomnia, nervousness, paresthesia, personality change, somnolence, tinnitus, tremor. Gastrointestinal: Anorexia, constipation, diarrhea, dry mouth, dysgeusia, dyspepsia, mild elevations of SGOT, SGPT, LDH, and alkaline phosphatase (see WARNINGS , Acute Hepatic Injury ), thirst, vomiting, weight increase. Dermatological: Petechiae, photosensitivity, pruritus, urticaria. Other: Amblyopia, CPK increase, dyspnea, epistaxis, eye irritation, hyperglycemia, hyperuricemia, impotence, muscle cramps, nasal congestion, nocturia, osteoarticular pain, polyuria, sexual difficulties. The following postmarketing events have been reported infrequently in patients receiving diltiazem hydrochloride: acute generalized exanthematous pustulosis, allergic reactions, alopecia, angioedema (including facial or periorbital edema), asystole, erythema multiforme (including Stevens-Johnson syndrome, toxic epidermal necrolysis), exfoliative dermatitis, extrapyramidal symptoms, gingival hyperplasia, hemolytic anemia, increased bleeding time, leukopenia, photosensitivity (including lichenoid keratosis and hyperpigmentation at sun-exposed skin areas), purpura, retinopathy, myopathy, and thrombocytopenia. In addition, ev...

adverse reactions table

Diltiazem Hydrochloride Extended-release Capsule (once-a-day dosage) Placebo-Controlled Angina and Hypertension Trials Combined Adverse ReactionsDiltiazem Hydrochloride Extended-release Capsule (once-a-day dosage) (n=607)Placebo (n=301)Headache5.4%5.0%Dizziness3.0%3.0%Bradycardia3.3%1.3%AV Block First Degree3.3%0.0%Edema2.6%1.3%Asthenia1.8%1.7%

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
61ebbccf-eedf-453b-940e-dba67b7a5fefProduct name420260107
a8d6eaa3-afcc-47e5-be12-0c9251fc8740Product name120251124
f6700316-a6ba-5e59-3413-8ede05ae58b9Product name720250625
8615f7a1-1e8f-8281-8601-d7a637926d1fProduct name420250522
3a9daa2f-bcd1-13de-a1b4-6172caa7f308Product name220240419
f7129636-cba8-86c2-8bfb-9e2e2a9c7628Product name220240314
378290be-e30f-0e68-1201-165e93c337e8Product name320231212
c733b56e-b0b5-4495-9857-0256a8242279Product name120220520
f4df4721-60d9-7fd2-a665-5c3c9f55af81Product name220171003

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
50090-3051-0CartiaXT30 in 1 BOTTLECAPSULE, EXTENDED RELEASE3010
50090-3051-1CartiaXT90 in 1 BOTTLE, PLASTICCAPSULE, EXTENDED RELEASE9010

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
50090-3051-0EA - Each50090-3051c99ad64a-1cd3-4ab0-9150-c67b9a6a5cf312019-05-02
50090-3051-1EA - Each50090-305191cc0175-1d68-42d4-802e-e0455d28cad812019-05-02

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
50090-3051CARTIA XT (DILTIAZEM HYDROCHLORIDE) CAPSULE, EXTENDED RELEASE [A-S MEDICATION SOLUTIONS]10Legacy NDC, 2 package rows20220208_795f516a-9fda-48ef-84a5-4e2e4ff7a756.zip

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYDailyMedSPL version
831226Cartia XT 120 MG 24HR Extended Release Oral Capsule, Once-A-DayPSN795f516a-9fda-48ef-84a5-4e2e4ff7a75610
831255Cartia XT 180 MG 24HR Extended Release Oral Capsule, Once-A-DayPSN795f516a-9fda-48ef-84a5-4e2e4ff7a75610
830861dilTIAZem HCl 120 MG 24HR Extended Release Oral CapsulePSN795f516a-9fda-48ef-84a5-4e2e4ff7a75610
830845dilTIAZem HCl 180 MG 24HR Extended Release Oral CapsulePSN795f516a-9fda-48ef-84a5-4e2e4ff7a75610
83122624 HR diltiazem hydrochloride 120 MG Extended Release Oral Capsule [Cartia]SBD795f516a-9fda-48ef-84a5-4e2e4ff7a75610
83125524 HR diltiazem hydrochloride 180 MG Extended Release Oral Capsule [Cartia]SBD795f516a-9fda-48ef-84a5-4e2e4ff7a75610
83086124 HR diltiazem hydrochloride 120 MG Extended Release Oral CapsuleSCD795f516a-9fda-48ef-84a5-4e2e4ff7a75610
83084524 HR diltiazem hydrochloride 180 MG Extended Release Oral CapsuleSCD795f516a-9fda-48ef-84a5-4e2e4ff7a75610
83122624 HR Cartia 120 MG Extended Release Oral CapsuleSY795f516a-9fda-48ef-84a5-4e2e4ff7a75610
83125524 HR Cartia 180 MG Extended Release Oral CapsuleSY795f516a-9fda-48ef-84a5-4e2e4ff7a75610
831226Cartia 120 MG 24 HR Extended Release Oral CapsuleSY795f516a-9fda-48ef-84a5-4e2e4ff7a75610
831255Cartia 180 MG 24 HR Extended Release Oral CapsuleSY795f516a-9fda-48ef-84a5-4e2e4ff7a75610
830861diltiazem HCl 120 MG 24 HR Extended Release Oral CapsuleSY795f516a-9fda-48ef-84a5-4e2e4ff7a75610
830845diltiazem HCl 180 MG 24 HR Extended Release Oral CapsuleSY795f516a-9fda-48ef-84a5-4e2e4ff7a75610

Packages#

Package NDC, 11-digit format, Description table
Package NDC11-digit formatDescriptionMarketing startMarketing endSampleExclude flagStatus
50090-3051-05009030510030 in 1 BOTTLEHistorical
50090-3051-15009030510190 CAPSULE, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (50090-3051-1) 2014-11-280000-00-00NoNoCurrent